Trial record 1 of 1 for:    SYR-472/OCT-002
Previous Study | Return to List | Next Study

SYR-472 Open-label Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01751360
Recruitment Status : Completed
First Posted : December 18, 2012
Last Update Posted : November 7, 2013
Information provided by (Responsible Party):

Brief Summary:
To evaluate the efficacy and safety of treatment with SYR-472 in diabetic patients.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus Drug: SYR-472 Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Primary Purpose: Treatment
Study Start Date : April 2013
Actual Primary Completion Date : August 2013
Actual Study Completion Date : August 2013

Arm Intervention/treatment
Experimental: SYR-472 100mg
SYR-472 100mg
Drug: SYR-472

Primary Outcome Measures :
  1. Blood Glucose [ Time Frame: 7 days ]
    Blood Glucose

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

-1. The participant is judged to be capable of understanding and complying with protocol requirements by the investigator or subinvestigator.

2. The participant can sign and date a written, informed consent form prior to the initiation of any study procedures.

Exclusion Criteria:

-1. The participant has concurrent serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease

. 2. The participant is assessed to be ineligible for the study by the investigator or subinvestigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01751360

Suita-shi, Osaka, Japan
Sponsors and Collaborators
Study Director: General Manager Takeda

Responsible Party: Takeda Identifier: NCT01751360     History of Changes
Other Study ID Numbers: SYR-472/OCT-002
U1111-1137-2768 ( Registry Identifier: UTN (WHO) )
JapicCTI-122024 ( Registry Identifier: JapicCTI (Japan) )
First Posted: December 18, 2012    Key Record Dates
Last Update Posted: November 7, 2013
Last Verified: November 2013

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases